The purpose of this pilot study was to examine the feasibility of conducting an energy conservation and activity management (ECAM) intervention for cancer treatment-related fatigue and describe patterns of cancer treatment-related fatigue for two groups undergoing active treatment, one receiving the ECAM intervention and a nonequivalent control group receiving standard care for cancer treatment-related fatigue. The ECAM group received 3 telephone sessions focusing on the provision of information about fatigue, development of an energy conservation plan, and evaluation of the plan's effectiveness. Data for the ECAM group were collected before treatment, at an expected fatigue high point during treatment, and an expected low point of fatigue after treatment. The nonequivalent control group lacked the pretreatment measure but had equivalent follow-up measurement points. The feasibility of conducting the ECAM intervention was supported by patient adherence in receiving all 3 sessions of the intervention and by their self-reports of its usefulness and plans to continue using ECAM skills. Patterns of fatigue differed for the ECAM study group and the nonequivalent control group, suggesting that the intervention moderates the expected rise in fatigue due to cancer therapy. A full-scale clinical trial is needed to evaluate the efficacy of the ECAM intervention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00002820-200210000-00001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A phase II study of anlotinib as first-line maintenance therapy for advanced ovarian cancer.
Anticancer Drugs
January 2025
Oncology Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province.
Article Synopsis
- Anlotinib has demonstrated positive effects in treating platinum-resistant ovarian cancer, but its role as a maintenance therapy after initial treatment was unclear.
- In a phase II clinical trial with 24 patients, those who received anlotinib after responding to chemotherapy had a median progression-free survival of 15.8 months and an overall survival of 43.8 months.
- The study indicated that anlotinib is a safe and effective option for maintenance therapy, showing promise in extending survival for patients with advanced ovarian cancer.
MT-Keyboard: A Bayesian Model-assisted Interval Design to Account for Toxicity Grades and Types for Phase I Trials.
Stat Biopharm Res
July 2024
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Conventionally, dose finding trials are based on dose-limiting toxicity (DLT) that only captures the most severe toxicities, e.g., treatment related grade 3 or higher toxicity according to the NCI Common Terminology Criteria for Adverse Events.
View Article and Find Full Text PDFEfficacy and safety of anlotinib as maintenance treatment in extensive-stage small cell lung cancer: a single-armed single center retrospective study.
Front Oncol
January 2025
Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Introduction: Patients with extensive-stage small cell lung cancer (ES-SCLC) have a poor Q6 prognosis and there is no standard protocol for maintenance treatment. Anlotinib as a third-line or beyond therapy for ES-SCLC was proved to be effective.
Methods: We retrospectively screened of patients with ES-SCLC who started receiving anlotinib as first-line or second-line therapy at the Second Affiliated Hospital of Chongqing Medical University from November 2018 to December 2022.
Dynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma.
J Comput Assist Tomogr
January 2025
Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT.
Background: Treatment-related changes may occur due to radiation and temozolomide in glioblastoma and can mimic tumor progression on conventional MRI. DCE-MRI enables quantification of the extent of blood-brain barrier (BBB) disruption, providing information about areas of suspicious postcontrast T1 enhancement. We compared DCE-MRI processing methods for distinguishing true disease progression from pseudoprogression in high-grade gliomas (HGGs).
View Article and Find Full Text PDFInfluence of religion and spirituality on head and neck cancer patients and their caregivers: a protocol for a scoping review.
Syst Rev
January 2025
Preventive Oral Health Unit, National Dental Hospital (Teaching) Sri Lanka, Ward Place, Colombo 7, Sri Lanka.
Introduction: Head and neck cancers (HNC) are devastating, thus imposing a negative impact on the appearance of an individual as well as vital activities such as eating, swallowing, speaking, and breathing. Therefore, HNC patients undergo distress, while their caregivers become overburdened. Religion and spirituality can be helpful for patients and their caregivers from diverse cultural backgrounds to cope with cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!